Rifampicin is a potent inducer of CYP3A4, the primary enzyme responsible for arteether metabolism. Co-administration can significantly decrease arteether plasma concentrations, leading to reduced efficacy and potential treatment failure for malaria.
Avoid concomitant use. If rifampicin is essential, consider alternative antimalarial treatments or closely monitor for treatment failure and consider increasing arteether dose if clinically appropriate and safe, though this is not well-studied.
Ritonavir is a potent inhibitor of CYP3A4. Co-administration can significantly increase arteether plasma concentrations, potentially leading to increased risk of dose-dependent adverse effects, including cardiotoxicity (QT prolongation) and neurotoxicity.
Avoid concomitant use if possible. If co-administration is unavoidable, consider reducing the arteether dose and closely monitor for adverse effects, including ECG changes and neurological symptoms. Therapeutic drug monitoring for arteether, if available, would be beneficial.
AmiodaroneModerate
Database
Both arteether and amiodarone can prolong the QT interval. Co-administration increases the risk of additive QT prolongation, potentially leading to serious ventricular arrhythmias like Torsades de Pointes.
Avoid concomitant use if possible. If unavoidable, perform baseline and regular ECG monitoring, monitor electrolytes (potassium, magnesium), and consider alternative antiarrhythmic or antimalarial agents. Use with extreme caution.
CarbamazepineModerate
Database
Carbamazepine is a moderate inducer of CYP3A4. Co-administration may reduce arteether plasma concentrations, potentially leading to decreased antimalarial efficacy.
Monitor for signs of treatment failure. Consider alternative antimalarial agents or a different anticonvulsant if possible. If co-administration is necessary, close clinical and parasitological monitoring is recommended.
ClarithromycinModerate
Database
Clarithromycin is a moderate inhibitor of CYP3A4. Co-administration may increase arteether plasma concentrations, potentially increasing the risk of adverse effects.
Monitor for increased adverse effects of arteether. Consider reducing the arteether dose if co-administration is necessary. Use with caution.
HaloperidolModerate
Database
Both arteether and haloperidol can prolong the QT interval. Co-administration increases the risk of additive QT prolongation, potentially leading to serious ventricular arrhythmias.
Avoid concomitant use if possible. If unavoidable, perform baseline and regular ECG monitoring, monitor electrolytes, and consider alternative antipsychotic or antimalarial agents. Use with caution.
ItraconazoleModerate
Database
Itraconazole is a potent inhibitor of CYP3A4. Co-administration can increase arteether plasma concentrations, potentially increasing the risk of adverse effects.
Monitor for increased adverse effects of arteether. Consider reducing the arteether dose if co-administration is necessary. Use with caution.
KetoconazoleModerate
Database
Ketoconazole is a potent inhibitor of CYP3A4. Co-administration can increase arteether plasma concentrations, potentially increasing the risk of adverse effects.
Monitor for increased adverse effects of arteether. Consider reducing the arteether dose if co-administration is necessary. Use with caution.
MefloquineModerate
Database
Both arteether and mefloquine can cause neurotoxicity (e.g., dizziness, vertigo, seizures) and cardiotoxicity (QT prolongation). Co-administration may increase the incidence and severity of these adverse effects.
While often used sequentially in malaria treatment, concurrent use should be avoided. If sequential use, ensure a washout period if possible, and monitor closely for neurological and cardiac adverse events.
PhenytoinModerate
Database
Phenytoin is a moderate inducer of CYP3A4. Co-administration may reduce arteether plasma concentrations, potentially leading to decreased antimalarial efficacy.
Monitor for signs of treatment failure. Consider alternative antimalarial agents or a different anticonvulsant if possible. If co-administration is necessary, close clinical and parasitological monitoring is recommended.
QuinidineModerate
Database
Both arteether and quinidine can prolong the QT interval. Co-administration increases the risk of additive QT prolongation, potentially leading to serious ventricular arrhythmias like Torsades de Pointes.
Avoid concomitant use if possible. If unavoidable, perform baseline and regular ECG monitoring, monitor electrolytes (potassium, magnesium), and consider alternative antiarrhythmic or antimalarial agents. Use with extreme caution.
Grapefruit JuiceMild
Database
Grapefruit juice can inhibit intestinal CYP3A4, potentially leading to a modest increase in arteether bioavailability and plasma concentrations.
Advise patients to avoid consuming grapefruit juice during arteether treatment, especially if they are prone to adverse effects or on higher doses.